Are These At The Top Of Your Watch List This Week?
Penny stocks remain one of the high points in the stock market today. After a huge breakout yesterday from WEI and previous to that, KXIN, there’s definitely a fervor for small-cap stocks right now. But there are more than just 1-day breakouts to look for. There are new industry trends and sector trends to keep in mind that can play a huge role in trading.
More recently, we’ve seen spikes in biotech, mining, energy, and tech stocks. When it comes to playing sector momentum, it’s important to see what catalysts are in play. Does it stem from a government-centric headline? Is it a company-specific headline? Or is it something totally different? Basically, you’re looking at anything that could act as a catalyst. However, as we’ve seen this week, sometimes it’s just the fact that a penny stock has a low float and traders are searching for stocks with similar share structures.
- 4 Biotech Penny Stocks To Watch Before The End Of The Week
- Are These Epicenter Penny Stocks To Buy Or Avoid? 1 Up 196% YTD
One of the key topics right now is a pending stimulus and the upcoming presidential election. The broader markets remain at odds on a daily basis. With this recent bout of volatility though, traders are finding new opportunities with small-cap stocks. The big thing to factor in is the risk/reward of each trade. Look for continuous and consistent volume, technical or fundamental catalysts, and even what the rumor mill is saying. Heading into the second half of the week, are these on your list of penny stocks right now?
Penny Stocks To Watch Right Now: GT Biopharma Inc.
GT Biopharma Inc. (GTBP Stock Report) has been one of the top biotech penny stocks to watch recently. The immuno-oncology company focuses on targeted therapies utilizing its a platform called TriKE™. It’s what the company’s GTB-3550 is built on and is being evaluated for treating acute myeloid leukemia in a Phase I/II trial right now. A few weeks back the company updated on its latest Dose Level 3 results. Not only did the company find a favorable outcome to this dose, but it also said the patient will be re-treated with an additional round of GTB-3550 therapy at the 25mcg/kg/day dose.
While this has garnered significant attention over the last few weeks, the company’s TriKE™ platform is becoming a much more recent focus overall. TriKE™ has been evaluated in ovarian, breast, prostate, pancreatic ductal adenocarcinoma and lung cancer models. The company has also recently brought on new Advisory Board members to help expand the therapeutic indications for TriKE ™ to non-hematologic cancers such as prostate.
Wednesday, GT Biopharma released the publication of “NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo” in the journal Cancers, volume 12, issue 9, page 2659; (https://doi. org/10.3390/cancers12092659).
B7H3 is highly expressed on the surface of several types of cancers. The findings presented indicate that a B7H3-targeted TriKE™ has the potential to enhance natural killer (NK) cell immunotherapy in solid tumor settings, and supports its further clinical development. This latest development adds to a string of key milestones reached by the company since the end of September.
Penny Stocks To Watch: Neos Therapeutics Inc.
Shares of Neos Therapeutics Inc. (NEOS Stock Report) have been on the move for the better part of the last 3 days. On Wednesday, NEOS stock saw its biggest surge yet reaching early morning highs of $0.75. The company a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products.
Its Adzenys XR-ODT® (amphetamine), Cotempla XR-ODT® (methylphenidate), and Adzenys-ER® (amphetamine) are all for the treatment of ADHD. The Company also has a development candidate, NT0502, for the treatment of sialorrhea in patients with neurological conditions.
There haven’t been many recent headlines from the company. But as I’m sure you’ve seen, the surge of interest in biotech stocks has continued growing in October. What’s more is that this quarter, Phase 1 single ascending and multiple ascending dose trials are set to begin. for NT0502. The multi-part study will include single ascending and multiple ascending dose cohorts. This was brought up in the company’s last earnings report. Also something to note from those earnings was the improvement in cash contribution from its ADHD portfolio.
“Neos reported a 5.8% growth to $128 in blended net revenue per pack for its two core commercial ADHD products, Adzenys XR-ODT®, and Cotempla XR-ODT®, for the three months ended June 30, 2020 compared to the same period in 2019.”
Penny Stocks To Watch: Novan, Inc.
Novan, Inc. (NOVN Stock Report) is another one of the penny stocks to watch recently. The company announced positive in vitro results of its NITRICIL™ platform technology earlier this month. The results showed the potential efficacy of its NITRICIL™ as an antiviral against SARS-CoV-2. Novan initiated in vitro assessments targeting the reduction of viral burden on human bronchial epithelial cells to evaluate NITRICIL™ as a potential nasal treatment option.
This week the company announced that management will present at a key opinion leader roundtable next Tuesday. In addition to the KOL roundtable discussion, members of the management team will host one-on-one meetings with investors. The recent excitement surrounding the latest findings has Novan management optimistic on its platform.
“COVID-19 continues to have a major ongoing impact on global health and there remains a direct need for a safe and effective antiviral therapy. The naturally occurring antiviral effects of nitric oxide and the results we have generated from this assessment, provide us with confidence that our NITRICIL™ platform technology may be an effective treatment for COVID-19. We also believe the data from this sophisticated model of the human respiratory tract demonstrate a high potential for clinical translation.”Paula Brown Stafford, Chairman and Chief Executive Officer of Novan
Novan plans to initiate Chemistry, Manufacturing, and Controls work with a global leader in providing integrated services, delivery technologies and manufacturing solutions. The aim is to develop an intranasal formulation of berdazimer sodium for use in the company’s COVID-19 program.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), GT Biopharma is required to pay $200,000 per month for 4 months of services, $400,000 of which has already been paid for 2 months of services (first and last month) for a period from September 22, 2020 to January 22, 2021. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).